{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:46:05Z","timestamp":1793807165218,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Currently, the criteria used to classify patients with SJIA are different from those used for AOSD. However, it has been recognized that the existing terms are too narrow, subdividing the Still\u2019s population unnecessarily between pediatric-onset and adult-onset disease and excluding an appreciable group of children in whom overt arthritis is delayed or absent. Government regulators and insurers rely upon the guidance of subject experts to provide disease definitions, and when these definitions are flawed, to provide new and better ones. The classification session at the NextGen 2022 conference helped to serve this purpose, establishing the need for a revised definitional system that transcends the fault lines that remain in existing definitions.<\/jats:p>","DOI":"10.1186\/s12969-023-00864-1","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:02:35Z","timestamp":1704456155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic\/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still\u2019s disease"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2126-3702","authenticated-orcid":false,"given":"Peter A.","family":"Nigrovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"de Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J.","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"864_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/095952879708000106","volume":"80","author":"GF Still","year":"1897","unstructured":"Still GF. On a Form of Chronic Joint Disease in Children. Med Chir Trans. 1897;80:47\u201360.","journal-title":"Med Chir Trans"},{"issue":"2 Suppl","key":"864_CR2","first-page":"195","volume":"20","author":"EJ Brewer Jr","year":"1977","unstructured":"Brewer EJ Jr, Bass J, Baum J, Cassidy JT, Fink C, Jacobs J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977;20(2 Suppl):195\u20139.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"864_CR3","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"key":"864_CR4","doi-asserted-by":"crossref","unstructured":"Case SM, Nigrovic PA. Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis. Paediatr Drugs. 2022;24(3):185\u201391.","DOI":"10.1007\/s40272-022-00496-0"},{"issue":"3","key":"864_CR5","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992;19(3):424\u201330.","journal-title":"J Rheumatol"},{"issue":"7","key":"864_CR6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64(7):1001\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"864_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-017-0157-1","volume":"15","author":"Y Kimura","year":"2017","unstructured":"Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, et al. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatr Rheumatol Online J. 2017;15(1):23.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"864_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019;46(2):190\u20137.","journal-title":"J Rheumatol"},{"key":"864_CR9","doi-asserted-by":"crossref","unstructured":"Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021;17(5):257\u201369.","DOI":"10.1038\/s41584-021-00590-6"},{"issue":"9","key":"864_CR10","first-page":"189","volume":"9","author":"BM Ansell","year":"1959","unstructured":"Ansell BM, Bywaters EG. Prognosis in Still\u2019s disease. Bull Rheum Dis. 1959;9(9):189\u201392.","journal-title":"Bull Rheum Dis"},{"issue":"3","key":"864_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/ard.26.3.185","volume":"26","author":"EG Bywaters","year":"1967","unstructured":"Bywaters EG. Heberden Oration, 1966 Categorization in medicine: a survey of Still\u2019s disease. Ann Rheum Dis. 1967;26(3):185\u201393.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"864_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard.37.2.107","volume":"37","author":"BM Ansell","year":"1978","unstructured":"Ansell BM. Heberden Oration, 1977. Chronic arthritis in childhood. Ann Rheum Dis. 1978;37(2):107\u201320.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"864_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/ard.30.2.121","volume":"30","author":"EG Bywaters","year":"1971","unstructured":"Bywaters EG. Still\u2019s disease in the adult. Ann Rheum Dis. 1971;30(2):121\u201333.","journal-title":"Ann Rheum Dis"},{"key":"864_CR14","doi-asserted-by":"crossref","unstructured":"Ruscitti P, Natoli V, Consolaro A, Caorsi R, Rosina S, Giancane G, et al. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. Rheumatology (Oxford). 2022;61(10):4124\u20139.","DOI":"10.1093\/rheumatology\/keac027"},{"issue":"2 Pt 1","key":"864_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0022-3476(05)80427-5","volume":"120","author":"R Schneider","year":"1992","unstructured":"Schneider R, Lang BA, Reilly BJ, Laxer RM, Silverman ED, Ibanez D, et al. Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J Pediatr. 1992;120(2 Pt 1):200\u20135.","journal-title":"J Pediatr"},{"issue":"8","key":"864_CR16","first-page":"553","volume":"30","author":"P Mozziconacci","year":"1983","unstructured":"Mozziconacci P, Prieur AM, Hayem F, Oury C. Articular prognosis of the systemic form of chronic juvenile arthritis (100 cases). Annales de pediatrie. 1983;30(8):553\u20136.","journal-title":"Annales de pediatrie"},{"issue":"2","key":"864_CR17","first-page":"91","volume":"41","author":"AM Prieur","year":"1984","unstructured":"Prieur AM, Bremard-Oury C, Griscelli C, Mozziconacci P. Prognosis of the systemic forms of juvenile chronic arthritis. Apropos of 100 cases. Archives francaises de pediatrie. 1984;41(2):91\u20137.","journal-title":"Archives francaises de pediatrie."},{"issue":"3","key":"864_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3899\/jrheum.120386","volume":"40","author":"RA Russo","year":"2013","unstructured":"Russo RA, Katsicas MM. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol. 2013;40(3):329\u201334.","journal-title":"J Rheumatol"},{"issue":"2","key":"864_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","volume":"70","author":"J Pouchot","year":"1991","unstructured":"Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, et al. Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118\u201336.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"864_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MD.0000000000000021","volume":"93","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91\u20139.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"864_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/acr.22194","volume":"66","author":"H Ichida","year":"2014","unstructured":"Ichida H, Kawaguchi Y, Sugiura T, Takagi K, Katsumata Y, Gono T, et al. Clinical manifestations of Adult-onset Still\u2019s disease presenting with erosive arthritis: Association with low levels of ferritin and Interleukin-18. Arthritis Care Res (Hoboken). 2014;66(4):642\u20136.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"864_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12916-016-0738-8","volume":"14","author":"P Ruscitti","year":"2016","unstructured":"Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccia F, Liakouli V, et al. Adult-onset Still\u2019s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14(1):194.","journal-title":"BMC Med"},{"issue":"13","key":"864_CR23","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss ES, Girard-Guyonvarc\u2019h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442\u201355.","journal-title":"Blood"},{"issue":"7","key":"864_CR24","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3899\/jrheum.120079","volume":"39","author":"HA Kim","year":"2012","unstructured":"Kim HA, An JM, Nam JY, Jeon JY, Suh CH. Serum S100A8\/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still\u2019s disease. J Rheumatol. 2012;39(7):1399\u2013406.","journal-title":"J Rheumatol"},{"issue":"3","key":"864_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1067\/mpd.2003.110","volume":"142","author":"AA Grom","year":"2003","unstructured":"Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003;142(3):292\u20136.","journal-title":"J Pediatr"},{"issue":"10","key":"864_CR26","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3899\/jrheum.111500","volume":"39","author":"JH Park","year":"2012","unstructured":"Park JH, Kim HS, Lee JS, Kim JJ, Jung KH, Park YW, et al. Natural killer cell cytolytic function in Korean patients with adult-onset Still\u2019s disease. J Rheumatol. 2012;39(10):2000\u20137.","journal-title":"J Rheumatol"},{"issue":"6","key":"864_CR27","doi-asserted-by":"publisher","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","volume":"58","author":"SJ Vastert","year":"2019","unstructured":"Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Osterling Koskinen L, Kullenberg T, et al. Anakinra in children and adults with Still\u2019s disease. Rheumatology (Oxford). 2019;58(6):vi9\u201322.","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"864_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.40350","volume":"70","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Raychaudhuri S, Thompson SD. Genetics and the classification of arthritis in adults and children. Arthritis Rheumatol. 2018;70(1):7\u201317.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"864_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021;17(5):257\u201369.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"864_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.revmed.2019.06.001","volume":"40","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux Y, Georgin-Lavialle S, Seve P, Belot A, Fautrel B. It is time to reconcile systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. La Revue de medecine interne. 2019;40(10):635\u20136.","journal-title":"La Revue de medecine interne"},{"issue":"7","key":"864_CR31","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol. 2019;71(7):1163\u201373.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"864_CR32","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034\u201343.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"864_CR33","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/art.40442","volume":"70","author":"NM Ter Haar","year":"2018","unstructured":"Ter Haar NM, Tak T, Mokry M, Scholman RC, Meerding JM, de Jager W, et al. Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2018;70(6):943\u201356.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"864_CR34","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505\u201315.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"864_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","volume":"61","author":"M Shimizu","year":"2013","unstructured":"Shimizu M, Nakanishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61(2):345\u20138.","journal-title":"Cytokine"},{"issue":"1","key":"864_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/art.38877","volume":"67","author":"SM Wakil","year":"2015","unstructured":"Wakil SM, Monies DM, Abouelhoda M, Al-Tassan N, Al-Dusery H, Naim EA, et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2015;67(1):288\u201395.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"864_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/ni.3532","volume":"17","author":"MZ Cader","year":"2016","unstructured":"Cader MZ, Boroviak K, Zhang Q, Assadi G, Kempster SL, Sewell GW, et al. C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nat Immunol. 2016;17(9):1046\u201356.","journal-title":"Nat Immunol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00864-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00864-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00864-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T16:05:53Z","timestamp":1706889953000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00864-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":37,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00864-1","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"5 January 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the manuscript and provided their consent to publish. All the patients mentioned in the manuscript gave their permissions to use full names.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PAN received investigator-initiated research grants from Bristol-Myers Squibb (BMS), Pfizer, and Novartis; consulting from BMS, Cerecor, Exo Therapeutics, Miach Orthopedics, Novartis, and Pfizer; royalties from UpToDate Inc. and the American Academy of Pediatrics; and salary support from the Childhood Arthritis and Rheumatology Research Alliance. FDB has received research grants from SOBI, Novartis, Roche, Sanofi, consultancies from Sobi, Novartis.Roche. YK has received investigator-initiated research grant support (awarded to CARRA) from Genentech, Inc., and served on an advisory board for SOBI; royalties from UpToDate Inc, and salary support from the Childhood Arthritis and Rheumatology Research Alliance. DJL\u2019s institution, the Cincinnati Children\u2019s Hospital Medical Center, has received research grants from BMS, Janssen, Novartis, Pfizer Inc., Roche and UBC; and has received consulting fees or other remuneration from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer Inc., Roche, and UBC for the work of DJL. DJL is a member of the Data Safety and Monitoring Boards for studies funded by the National Institutes of Health and the Canadian Arthritis Society. SJV received investigator-initiated research grants from SOBI and consultancy\/speaker fees from SOBI and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}